(Q40611414)
Statements
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer (English)
E Raymond
M Gatineau
K Meely
S Mekhaldi
P Pautier
M Ducreux
O Rixe